PfizerPFE
PFE
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
42% more first-time investments, than exits
New positions opened: 339 | Existing positions closed: 239
1% more funds holding
Funds holding: 2,871 [Q3] → 2,909 (+38) [Q4]
0.48% more ownership
Funds ownership: 65.34% [Q3] → 65.82% (+0.48%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 40 [Q3] → 40 (+0) [Q4]
7% less capital invested
Capital invested by funds: $108B [Q3] → $100B (-$7.61B) [Q4]
15% less call options, than puts
Call options by funds: $3.27B | Put options by funds: $3.87B
36% less repeat investments, than reductions
Existing positions increased: 918 | Existing positions reduced: 1,444
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$28
11%
upside
Avg. target
$29
13%
upside
High target
$29
15%
upside
2 analyst ratings
0 positive
0%
2 neutral
100%
0 negative
0%
UBS Colin Bristow 33% 1-year accuracy 5 / 15 met price target | 11%upside $28 | Neutral Maintained | 5 Feb 2025 |
Citigroup Andrew Baum 50% 1-year accuracy 3 / 6 met price target | 15%upside $29 | Neutral Maintained | 28 Jan 2025 |
Financial journalist opinion
Based on 68 articles about PFE published over the past 30 days
Neutral
Finbold
1 day ago
2 healthcare stocks to buy ahead of Trump's pharmaceutical tariffs
United States President Donald Trump has hinted that the pharmaceutical sector will likely be the next to be hit with tariffs. While announcing on March 28, Trump did not specify the date or rates involved, but the decision will likely trigger more market uncertainty.
Negative
Finbold
1 day ago
2 healthcare safe bets to buy ahead of Trump's pharmaceutical tariffs
United States President Donald Trump has hinted that the pharmaceutical sector will likely be the next to be hit with tariffs. While announcing on March 28, Trump did not specify the date or rates involved, but the decision will likely trigger more market uncertainty.
Neutral
The Motley Fool
1 day ago
Why I Just Bought These 3 Ultra-High-Yield Dividend Stocks
When a commercial aircraft encounters turbulence, a flight attendant will tell all passengers to return to their seats and buckle their seat belts. Some investors think a similar approach is appropriate when the stock market hits a rough patch.
Positive
Seeking Alpha
2 days ago
6 Ultra SWANs Potentially Set To Soar In 2025
The Dividend Kings Fortress Portfolio, composed exclusively of Ultra SWAN stocks (highest-quality blue chips), has delivered strong returns over the last six years. Just 20% of the holdings produced 75% of the profits, underscoring the importance of owning top-quality blue-chip stocks for long-term wealth creation. The carefully selected portfolio of growth and value Ultra SWANs - including Nvidia, Amazon, Brookfield Asset Management, Realty Income, Pfizer, and Federal Realty - offers upside potential.
Positive
The Motley Fool
3 days ago
Pfizer: Value Play or Past Its Prime?
Explore the exciting world of Pfizer (PFE -0.61%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Negative
Forbes
3 days ago
Did Pfizer Delay Covid Vaccine Announcement Until After 2020 Election? Here's What We Know.
Federal investigators are investigating claims suggesting Pfizer delayed announcing test results of its Covid vaccine until after the 2020 presidential election, the Wall Street Journal reported, bolstering a claim by President Donald Trump, who has claimed for years the company withheld vaccine results to impact his chances at reelection.
Neutral
Market Watch
3 days ago
Biotech stocks have been hit hard. Why they're a great value now.
Biotech is one of the U.S. stock market's most unloved sectors. But several indicators suggest that a bottom in sentiment could be near, and that's normally a good time to buy.
Negative
The Motley Fool
3 days ago
Why Pfizer Is My Largest Healthcare Position
Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't entirely warranted.
Negative
New York Post
4 days ago
Feds probe tip that Pfizer delayed announcing COVID vaccine's success until after 2020 election: report
The report said GSK's former head of vaccine development, Philip Dormitzer, who joined the company after working at rival Pfizer, had told his GSK colleagues about the delay.
Negative
Zacks Investment Research
4 days ago
Here's Why Pfizer (PFE) Fell More Than Broader Market
In the latest trading session, Pfizer (PFE) closed at $25.21, marking a -1.33% move from the previous day.
Charts implemented using Lightweight Charts™